Piper Jaffray analyst David is “staying bullish” on Bausch Health Companies after bring an investor group to meet with management at the company’s headquarters. The analyst continues to believe that visibility into Bausch’s longer-term EBITDA growth of at least in the mid-single digits is high, with key drivers including Xifaxan growth and contribution from new products. That translates into an attractive risk/reward profile at current valuation levels, Amsellem tells investors in a research note. He reiterates an Overweight rating on Bausch Health with a $28 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.